TWO HOURS PLASMA CONCENTRATION OF RIFAMPICIN IN PATIENTS OF NEWLY DIAGNOSED PULMONARY TUBERCULOSIS WITH AND WITHOUT DIABETES MELLITUS ON ANTI TUBERCULOSIS THERAPY– A CROSS-SECTIONAL STUDY.

Dr Dhruve Soni, Dr Sunil Kumar Mathur

Abstract


Aim

To estimate and compare rifampicin C2hr concentration in newly diagnosed pulmonary TB patients with and without DM on anti-tuberculosis therapy.

 Materials and methods: A cross-sectional study was done on 54 newly diagnosed pulmonary TB patients with and without DM on anti-TB drug therapy as per RNTCP.

Sample was collected 2 hours post dose administration. Separated plasma was stored in liquid nitrogen until the analysis. Estimation of rifampicin concentration was done using HPLC.

Result:

Rifampicin plasma levels at 2 hours post drug administration (C2hr) were below reference ( ≥ 8µg/ml) in 24(100%) of diabetics and 23(77%) of non-diabetics.

The mean Rifampicin Plasma C2hr ± SD of diabetic TB patients was significantly lower than the non-diabetic TB patients with values of 3.52±0.96 and 5.79±1.73 µg/ml.

Negative correlation was seen between RBS mg/dl and rifampicin plasma levels in diabetic and non-diabetic TB patients with Pearson correlation coefficient (r) of -0.74, p-value < 0.01 and -0.53, p-value < 0.01 respectively.

Conclusion:

 Plasma levels of rifampicin were below reference in all of the diabetics and most of non-diabetic TB patients. Higher doses of rifampicin may be required to achieve therapeutic concentration for TB therapy. Therapeutic drug monitoring should be considered for TB therapy in patients of TB with DM as comorbidity.


Keywords


Rifampicin, C2hr levels, Diabetes Mellitus, Tuberculosis.

Full Text:

PDF

References


Yates T, Khunti K. (2016). Epidemiology: The diabetes mellitus tsunami: worse than the 'Spanish flu' pandemic?. Nat Rev Endocrinol, 12: 377–378.

WHO. TB comorbidities and risk factors .(2017). Retrieved from www.who.int › tb › areas-of-work › treatment › risk-factors.

K. E. Dooley, R. E. Chaisson.( 2019). Tuberculosis and diabetes mellitus: convergence of two epidemics. The Lancet Infectious Diseases. 9(12), 737–746.

S. K. Heysell, J. L. Moore, S. J. Keller, et al.(2010).Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. Emerging Infectious Diseases,16(10), 1546–1553.

B. Alisjahbana, E. Sahiratmadja, E. J. Nelwan , et al.(2007).The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. Clinical Infectious Diseases ,45(4), 428–435.

Suo J1, Chang CE, Lin TP, et al.(1988). Minimal inhibitory concentrations of isoniazid, rifampin, ethambutol, and streptomycin against Mycobacterium tuberculosis strains isolated before treatment of patients in Taiwan. Am Rev Respir Dis,138(4),999-1001.

Van Ingen J, Aarnoutse RE, Donald PR et al. (2011). Why do we use 600 mg of rifampicin in tuberculosis treatment? Clin Infect Dis,52,e194–9.Retrieved from https://doi.org/10.1093/cid/cir184.

Peloquin C. Therapeutic drug monitoring: principles and applications in mycobacterial infections. Drug Therapy 1992; 22: 31–6.

Nijland HM, Ruslami R, Stalenhoef JE, et al.(2006). Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis,43,848–54.

Babalik A ,Ulus IH, Bakirci N, et al.(2013). Plasma concentration of Isoniazide and Rifampicin are decreased in adult pulmonary TB patients with DM .Antimicrob Agents Chemother, 57(11),5740–5742.

Heysell SK , Moore JL ,Staley D , et al.(2013). Early Therapeutic Drug Monitoring for Isoniazide and Rifampicin among Diabetics with Newly Diagnosed TB in Virginia,USA . Tuberc Res Treat, Volume 2013, Article ID 129723, 6 pages. Retrieved from https://doi.org/10.1155/2013/129723

Saranya P, Parthasarathy V, Hariprasad B, et al. (2016).Effect of DM on Rifampicin peak serum concentration. Int J Pharm PharmSci ,8( 10), 149-152.

Omamah Alfarisi, Vidya Mave, Sanjay Gaikwad, et al.(2018). Effect of Diabetes Mellitus on the Pharmacokinetics and Pharmacodynamics of Tuberculosis Treatment. Antimicrob Agents Chemother. Oct 24,62(11), e01383-18. Retrieved from https://doi.org/10.1128/AAC.01383-18.

Ruslami R, Nijland HM, Adhiarta IG, et al. (2010). Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. Antimicrob Agents Chemother, 54,1068–1074

Charlotte Seijger, Wouter Hoefsloot, Inge Bergsma-de Guchteneire et al. (2019). High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre.PLoS One, 14(3), e0213718. Retrieved from https://doi.org/10.1371/journal.pone.0213718.


Refbacks

  • There are currently no refbacks.